MedTrace Logo

Phase 3 Herniorrhaphy Study for Postoperative Analgesia (EPOCH 2)

NCT03237481 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 418

Last updated 2026-03-02

Study results available
· View outcomes & findings →

Summary

This is a Phase 3, randomized, double-blind, saline placebo- and active-controlled, multicenter study to evaluate the analgesic efficacy and safety of HTX 011 administered via local administration into the surgical site in subjects undergoing unilateral open inguinal herniorrhaphy.

Conditions

  • Postoperative Pain

Interventions

DRUG

HTX-011

HTX 011 (bupivacaine/meloxicam), 300 mg/9 mg by instillation

DRUG

Bupivacaine HCl

Bupivacaine HCl without epinephrine, 75 mg by injection

DRUG

Saline placebo

Saline placebo by instillation

DEVICE

Luer-lock applicator

Applicator for instillation

DEVICE

Vial access device

Device for withdrawal of drug product

Sponsors & Collaborators

  • Heron Therapeutics

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-07-31
Primary Completion
2017-12-22
Completion
2018-01-16
FDA Drug
Yes
FDA Device
Yes

Countries

  • United States
  • Belgium

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03237481 on ClinicalTrials.gov